CD274 and non-small cell lung carcinoma: Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein‐1 (PD‐1) and its receptor ligand‐1 (PD‐L1) have become a mainstay of treatment in NSCLC, particularly, in patients with advanced disease stages who lack druggable molecular alterations [3].